Loading organizations...
§ Venture Capital
Corporate venture capital firm and VC investor making strategic investments in companies within the biotech and life sciences sectors.
404 Bio functions as a corporate venture capital firm, deploying strategic investments exclusively within the biopharmaceutical sector. The firm targets companies whose innovations align with its corporate objectives, serving as a financial and strategic partner. This model directly supports the development and progression of biological and pharmaceutical advancements.
Public details concerning the specific founders of 404 Bio and the initial insight for its establishment are not widely available. Its operational history indicates a single recorded transaction, reflecting a concentrated period of activity. As a corporate venture capital entity, its precise genesis and early leadership lack extensive public documentation.
The firm's limited portfolio includes biopharmaceutical ventures, notably an investment in Turnstone Biologics. 404 Bio's vision involves channeling capital to foster innovation within the biopharmaceutical domain. It seeks to support enterprises capable of delivering significant advancements in healthcare solutions, contributing to the deployment of novel therapies and biotechnologies.
404 Bio has 1 tracked investment across 1 company. The latest tracked deal is $80.0M Series D in Turnstone Biologics in July 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2021 | Turnstone Biologics | $80.0M Series D | Santhosh Palani, Phd, CFA, Point72 | KohFounders, Sofinnova Investments, VenBio Partners, Venrock, Versant Ventures, Brace Pharma Capital, Caas Capital Management, Eventide Asset Management, F Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Ridgeback Capital Investments, Sectoral Asset Management, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital |